In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4+ T lymphocytes

Scandinavian Journal of Immunology

Volumn 66, Issue 4, 2007, Pages 451-457

  Ellingsen, T ^a   Hornung, N ^b   Moller B K ^a   Hjelm Poulsen, J ^c   Stengaard Pedersen, K ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b RANDERS REGIONAL HOSPITAL   (Denmark)

^c HOLBÆK HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; METHOTREXATE;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, CD26; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; MALE; METHOTREXATE; MIDDLE AGED; MONOCYTES; RHEUMATOID FACTOR; STATISTICS, NONPARAMETRIC;

EID: 34548545066     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01966.x     Document Type: Article

References (54)

1. Morimoto C, Torimoto Y, Levinson G et al. 1F7. a novel cell surface molecule involved in helper function of CD4 cells. J Immunol 1989 143 : 3430 9.
2. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol 2001 54 : 249 64.
3. Gerli R, Muscat C, Bertotto A et al. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin Immunol Immunopathol 1996 80 : 31 7.
4. Mizokami A, Eguchi K, Kawakami A et al. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. J Rheumatol 1996 23 : 2022 6.
5. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998 161 : 55 70.
6. Muscat C, Bertotto A, Agea E et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994 98 : 252 6.
7. + T cells through CD26: the ADA-binding epitope is not essential for complete signaling. J Leukoc Biol 1995 58 : 325 30.
8. Morimoto C, Lord CI, Zhang C et al. Role of CD26/dipeptidyl peptidase IV in human immunodeficiency virus type 1 infection and apoptosis. Proc Natl Acad Sci U S A 1994 91 : 9960 4.
9. Tanaka T, Duke-Cohan JS, Kameoka J et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci U S A 1994 91 : 3082 6.
10. Seitzer U, Scheel-Toellner D, Mattern T et al. Staining pattern of seven monoclonal anti-CD26 antibodies in leprosy: implications for the use of CD26 as a surrogate marker of a human Th1-like reaction. Virchows Arch 1998 432 : 343 7.
11. Salgado FJ, Vela E, Martin M et al. Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes. Cytokine 2000 12 : 1136 41.
12. Cordero OJ, Salgado FJ, Vinuela JE et al. Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes. Immunobiology 1997 197 : 522 33.
13. Willheim M, Ebner C, Baier K et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets. J Allergy Clin Immunol 1997 100 : 348 55.
14. Reinhold D, Bank U, Buhling F et al. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-beta 1 (TGF-beta 1) in stimulated mouse splenocytes and thymocytes. Immunol Lett 1997 58 : 29 35.
15. Seitzer U, Scheel-Toellner D, Hahn M et al. Comparative study of CD26 as a Th1-like and CD30 as a potential Th2-like operational marker in leprosy. Adv Exp Med Biol 1997 421 : 217 21.
16. Scheel-Toellner D, Richter E, Toellner KM et al. CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon gamma. Lab Invest 1995 73 : 685 90.
17. Wrenger S, Faust J, Friedrich D et al. Attractin, a dipeptidyl peptidase IV/CD26-like enzyme, is expressed on human peripheral blood monocytes and potentially influences monocyte function. J Leukoc Biol 2006 80 : 621 9.
18. + T cells that exhibit a transendothelial migratory capacity. J Immunol 1995 154 : 3062 77.
19. Masuyama J, Yoshio T, Suzuki K et al. Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med 1999 189 : 979 90.
20. Proost P, Menten P, Struyf S et al. Cleavage by CD26/dipeptidylpeptidase IV converts LD78-beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000 96 : 1674 80.
21. Iwata S, Yamaguchi N, Munakata Y et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes towards RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999 11 : 417 26.
22. Oravecz T, Pall M, Roderiquez G et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med 1997 186 : 1865 72.
23. Proost P, De Meester I, Schols D et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998 273 : 7222 7.
24. Van Damme J, Struyf S, Wuyts A et al. The role of CD26/DPPIV in chemokine processing. Chem Immunol 1999 72 : 42 56.
25. Struyf S, Menten P, Lenaerts JP et al. Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-1alpha to the CC chemokine receptors 1, 3 and 5 affect their anti-HIV-1 activity and chemotactic potencies for neutrophils and eosinophils. Eur J Immunol 2001 31 : 2170 8.
26. Proost P, Schutyser E, Menten P et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signalling and lymphocyte chemotaxis while preserving antiangiogenic properties. Blood 2001 98 : 3554 61.
27. Guan E, Wang J, Norcross MA. Amino-terminal processing of MIP-1beta/CCL4 by CD26/dipeptidyl-peptidase IV. J Cell Biochem 2004 92 : 53 64.
28. Hoffmann T, Faust J, Neubert K et al. Dipeptidyl peptidase IV (CD26) and aminopeptidase N (CD13) catalyzed hydrolysis of cytokines and peptides with N-terminal cytokine sequences. FEBS Lett 1993 336 : 61 4.
29. Mantle D, Falkous G, Walker D. Quantification of protease activities in synovial fliud and from rheumatoid arthritis and osteoarthritis cases: comparison with antioxidant and free radical damage markers. Clin Chim Acta 1999 284 : 45 58.
30. Cordero OJ, Salgado FJ, Mera-Varela A et al. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 2001 21 : 69 74.
31. Cuchacovich M, Gatica H, Pizzo SV et al. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 2002 19 : 673 80.
32. Busso N, Wagtmann N, Herling C et al. Circulating CD26 is negatively associated with Inflammation in Human and Experimental Arthritis. Am J Pathol 2005 166 : 433 42.
33. Ohnuma K, Inoue H, Uchiyama M et al. T cell activation via CD26 and caveolin-1 in rheumatoid synovium. Mod Rheumatol 2006 16 : 3 13.
34. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 31 : 315 24.
35. van Riel PLCM, The EULAR International Standing Committee for International Clinical Studies Including Therapeutic Trials - ESCISIT EULAR Handbook of Clinical Assessments in Rheumatoid Arthritis. Alphen aan de Rijn : Van Zuiden Communications B.V., 2004 : 1 53.
36. Wolfe F, Kleinheksel SM, Cathey MA et al. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. J Rheumatol 1988 15 : 1480 8.
37. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993 36 : 729 40.
38. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 38 : 727 35.
39. + T-lymphocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders. Ann Rheum Dis 2006 66 : 151 7.
40. Current Protocols in Immunology Appendix A3. USA : Greene Publishing Associates and Wiley-Intersciences, 1991.
41. Barrera P, Haagsma CJ, Boerbooms AM et al. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995 34 : 747 55.
42. Seitz M, Loetscher P, Dewald B et al. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8 -markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 1996 23 : 1512 6.
43. Mack M, Bruhl H, Gruber R et al. Predominance of mononuclear cells expressing the chemokine receptor CCR5 in synovial effusions of patients with different forms of arthritis. Arthritis Rheum 1999 42 : 981 8.
44. Barrera P, Boerbooms AM, Janssen EM et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993 36 : 1070 9.
45. Boiardi L, Macchioni P, Meliconi R et al. Relationship between serum RANTES levels and radiological progression in rheumatoid arthritis patients treated with methotrexate. Clin Exp Rheumatol 1999 17 : 419 25.
46. Alarcon GS, Schrohenloher RE, Bartolucci AA et al. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 1990 33 : 1156 61.
47. Hornung N, Stengaard-Pedersen K, Ehrnrooth E et al. The effects of low-dose methotrexate on thymidylate synthetase activity in human peripheral blood mononuclear cells. Clin Exp Rheumatol 2000 18 : 691 8.
48. Ribbens C, Andre B, Jaspar JM et al. Matrix metalloproteinase-3 serum levels are correlated with disease activity and predict clinical response in rheumatoid arthritis. J Rheumatol 2000 27 : 888 93.
49. Majumdar S, Aggarwal BB. Methotrexate suppresses NF-kappaB activation through inhibition of I-kappaBalpha phosphorylation and degradation. J Immunol 2001 167 : 2911 20.
50. Hawkes JS, Cleland LG, Proudman SM et al. The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J Rheumatol 1994 21 : 55 8.
51. Olsen NJ, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989 32 : 378 85.
52. Segal R, Caspi O, Tishler M et al. Short term effects of low dose methotrexate on macrophage function. J Rheumatol 1989 16 : 914 7.
53. Hirata S, Matsubara T, Saura R et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989 32 : 1065 73.
54. Yamasaki S, Ueki Y, Nakamura H et al. Effect of filtration leukocytapheresis therapy: modulation of white blood cell enzyme activities in patients with rheumatoid arthritis. Artif Organs 2002 26 : 378 84.